
    
      The treatment option in patients with platinum-resistant relapsed or metastatic squamous cell
      carcinoma of head and neck is limited. Previous randomized phase III study showed a
      borderline benefit of pemetrexed added to cisplatin. Therefore, we aim to evaluate the
      efficacy of pemetrexed in salvage setting.
    
  